E-LIB Suche - Ergebnisse für: Viganò, C

1

P1058 Safety and effectiveness of subcutaneous infliximab f..:

Mulinacci, G ; Pirola, L ; Piazza O Sed, N...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1904-i1905 , 2024

Link: https://doi.org/10.1093/..

2

P921 Maintenance of clinical, biochemical and transmural re..:

Piazza O Sed, N ; Maregatti, M C ; Pessarelli, T...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1679-i1679 , 2024

Link: https://doi.org/10.1093/..

3

P508 Pre-operative exposure to tofacitinib is as safe as bi..:

Dragoni, G ; Innocenti, T ; Amiot, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1005-i1006 , 2024

Link: https://doi.org/10.1093/..

4

P539 Assessment of VEdolizumab aNd Ustekinumab in Elderly p..:

Viola, A ; Ventimiglia, M ; Sparacino, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1059-i1061 , 2024

Link: https://doi.org/10.1093/..

5

BOC.03.2: ULTRASOUND MUSCLE ASSESSMENT FOR SARCOPENIA SCREE..:

Mulinacci, G. ; Pirola, L. ; Gandola, D....
Digestive and Liver Disease. 56 (2024) - p. S115 , 2024

Link: https://doi.org/10.1016/..

6

OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDER..:

Viola, A. ; Ventimiglia, M. ; Sparacino, A....
Digestive and Liver Disease. 56 (2024) - p. S161-S163 , 2024

Link: https://doi.org/10.1016/..

7

P908 Real-life effectiveness and safety of tofacitinib and ..:

Noviello, D ; Savarino, E ; Fries, W...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1660-i1661 , 2024

Link: https://doi.org/10.1093/..

8

P612 Switching from intravenous to subcutaneous VEDOlizumab..:

Ribaldone, D G ; Parisio, L ; Variola, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1185-i1185 , 2024

Link: https://doi.org/10.1093/..

9

P466 Ultrasound muscle assessment for sarcopenia screening ..:

Mulinacci, G ; Pirola, L ; Gandola, D...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i937-i938 , 2024

Link: https://doi.org/10.1093/..

10

P455 Comparison of two strategies for the management of pos..:

Dragoni, G ; Castiglione, F ; Bezzio, C...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i584-i585 , 2023

Link: https://doi.org/10.1093/..

11

P612 Lack of seroconversion following COVID-19 vaccination,..:

Macaluso, F S ; Principi, M ; Facciotti, F...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i741-i741 , 2023

Link: https://doi.org/10.1093/..

12

Nutritional optimization in medical and surgical treatment ..:

Viganò, C. ; Sampietro, G.M.
Digestive and Liver Disease. 55 (2023) 8 - p. 1026-1027 , 2023

Link: https://doi.org/10.1016/..

13

P674 Ustekinumab is the preferred biological agent in IBD p..:

Verstockt ., B ; Vieujean, S ; Truyens, M...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i805-i806 , 2023

Link: https://doi.org/10.1093/..

14

OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATI..:

Macaluso, F.S. ; Principi, M. ; Facciotti, F....
Digestive and Liver Disease. 55 (2023) - p. S124-S125 , 2023

Link: https://doi.org/10.1016/..

15

PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COV..:

Macaluso, F.S. ; Principi, M. ; Facciotti, F....
Digestive and Liver Disease. 54 (2022) - p. S64-S65 , 2022

Link: https://doi.org/10.1016/..